These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 10086646

  • 1. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
    Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K.
    Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
    [Abstract] [Full Text] [Related]

  • 2. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
    Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K.
    Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
    [Abstract] [Full Text] [Related]

  • 3. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Tameda Y, Nakano T.
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M, Nakano M.
    Cancer; 2000 Feb 01; 88(3):544-9. PubMed ID: 10649245
    [Abstract] [Full Text] [Related]

  • 5. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Watanabe K, Magario N, Yokoo T, Naraki T.
    Cancer; 1999 Feb 15; 85(4):812-8. PubMed ID: 10091758
    [Abstract] [Full Text] [Related]

  • 6. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K, Watanabe T, Aikawa K, Toshima M, Shibasaki K, Aoyagi Y.
    Hepatogastroenterology; 1998 Feb 15; 45(23):1737-41. PubMed ID: 9840138
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.
    Chin Med J (Engl); 2002 Jan 15; 115(1):42-5. PubMed ID: 11930656
    [Abstract] [Full Text] [Related]

  • 8. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.
    J Gastroenterol Hepatol; 2008 Oct 15; 23(10):1541-8. PubMed ID: 18422961
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A, Taniguchi K, Inoue S, Harada A, Nonami T, Watanabe K, Takagi H.
    Semin Surg Oncol; 1996 Oct 15; 12(3):160-3. PubMed ID: 8727604
    [Abstract] [Full Text] [Related]

  • 10. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M.
    Clin Gastroenterol Hepatol; 2009 Jan 15; 7(1):104-13. PubMed ID: 18849011
    [Abstract] [Full Text] [Related]

  • 11. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, Bang KT, Kim DW, Song IH.
    Korean J Hepatol; 2006 Sep 15; 12(3):404-11. PubMed ID: 16998292
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y.
    Am J Gastroenterol; 2006 Sep 15; 101(9):2038-43. PubMed ID: 16848811
    [Abstract] [Full Text] [Related]

  • 13. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
    Sakizono K, Oita T, Shibata Y, Tamura A, Kasakura S.
    Rinsho Byori; 1998 Sep 15; 46(9):936-41. PubMed ID: 9800480
    [Abstract] [Full Text] [Related]

  • 14. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K, Azuma M.
    Hepatogastroenterology; 1999 Sep 15; 46(28):2464-8. PubMed ID: 10522021
    [Abstract] [Full Text] [Related]

  • 15. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
    Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S, Makuuchi M.
    Int J Oncol; 2003 May 15; 22(5):969-75. PubMed ID: 12684661
    [Abstract] [Full Text] [Related]

  • 16. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R, Runge M, Stieber P, Meissner E.
    Anticancer Res; 1999 May 15; 19(4A):2489-93. PubMed ID: 10470180
    [Abstract] [Full Text] [Related]

  • 17. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS.
    Hepatology; 2003 May 15; 37(5):1114-21. PubMed ID: 12717392
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H.
    Cancer; 1996 May 01; 77(9):1781-6. PubMed ID: 8646674
    [Abstract] [Full Text] [Related]

  • 19. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N.
    Ann Surg Oncol; 2009 Oct 01; 16(10):2795-804. PubMed ID: 19669841
    [Abstract] [Full Text] [Related]

  • 20. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S, Morishita T, Shibata J, Sato T.
    Gan To Kagaku Ryoho; 1989 Apr 01; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.